Disclosing Secondary Findings from Pediatric Sequencing to Families: Considering the “Benefit to Families”

Borry P. Fryns J. P. Schotsmans P. Dierickx K. , “Carrier Testing in Minors: A Systematic Review of Guidelines and Position Papers,” European Journal of Human Genetics 14, no. 2 (2006): 133–138.

Wilfond B. Ross L. F. , “From Genetics to Genomics: Ethics, Policy, and Parental Decision-Making,” Journal of Pediatric Psychology 34, no. 6 (2009): 639–647; Ross L. F. Saal H. M. David K. L. , “Technical Report: Ethical and Policy Issues in Genetic Testing and Screening of Children,” Genetics in Medicine 15, no. 3 (2013): 234–245.

Green R. C. Berg J. S. Grody W. W. , “ACMG Recommendations for Reporting of Incidental Findings in Clinical Exome and Genome Sequencing,” Genetics in Medicine 15, no.7 (2013): 565–574.

Directors of the American College of Medical Genetics, “ACMG Policy Statement: Updated Recommendations Regarding Analysis and Reporting of Secondary Findings in Clinical Genome-Scale Sequencing,” Genetics in Medicine 17, no. 1 (2015): 68–69.

Burke W. Antommaria A. H. Bennett R. , “Recommendations for Returning Genomic Incidental findings? We Need to Talk!” Genetics in Medicine 15, no. 11 (2013): 854–859; Clayton E. W. McCullough L. B. Biesecker L. G. , “Addressing the Ethical Challenges in Genetic Testing and Sequencing of Children,” American Journal of Bioethics 14, no. 3 (2014): 3–9.

Green , supra note 3.

Burke , supra note 5.

American Society of Human Genetics Board of Directors and American College of Medical Genetics Board of Directors, “Points to Consider: Ethical, Legal, and Psychosocial Implications of Genetic Testing in Children and Adolescents,” American Journal of Human Genetics 57, no. 5 (1995): 1233–1241.

See, e.g., Davis D. S. , “Genetic Dilemmas and the Child's Right to an Open Future,” Hastings Center Report 27, no. 2 (1997): 7–15.

Ross , supra note 2.

American Society of Human Genetics Board of Directors and American College of Medical Genetics Board of Directors, supra note 8.

Wade C. H. Wilfond B. S. McBride C. M. , “Effects of Genetic Risk Information on Children's Psychosocial Wellbeing: A Systematic Review of the Literature,” Genetics in Medicine 12, no. 6 (2010): 317–326.

Fanos J. H. Johnson J. P. , “Perception of Carrier Status by Cystic Fibrosis Siblings,” American Journal of Human Genetics 57, no. 2 (1995): 431–438.

Meiser B. Dunn S. , “Psychological Impact of Genetic Testing for Huntington's Disease: An Update of the Literature,” Journal of Neurology, Neurosurgery, and Psychiatry 69, no. 5 (2000): 574–578.

Fanos J. H. , “Developmental Tasks of Childhood and Adolescence: Implications for Genetic Testing,” American Journal of Medical Genetics 71, no. 1 (1997): 22–28.

Green R. C. Roberts J. S. Cupples L. A. , “Disclosure of APOE Genotype for Risk of Alzheimer's Disease,” New England Journal of Medicine 361, no. 3 (2009): 245–254; Lautenbach D. M. Christensen K. D. Sparks J. A. Green R. C. , “Communicating Genetic Risk Information for Common Disorders in the Era of Genomic Medicine,” Annual Review of Genomics and Human Genetics 14 (2013): 491–513.

Davis , supra note 9.

Feinberg J. , “The Child's Right to an Open Future,” in Freedom & Fulfillment (Princeton, NJ: Princeton University Press, 1992): At 76–97.

Codori A. M. Brandt J. , “Psychological Costs and Benefits of Predictive Testing for Huntington's Disease,” American Journal of Medical Genetics 54, no. 3 (1994): 174–184; Quaid K. A. Brandt J. Folstein S. E. , “The Decision to be Tested for Huntington's Disease,” JAMA 257, no. 24 (1987): 3362–3360.

Wilfond Ross , supra note 2; Ross , supra note 2.

Wilfond B. , “Predicting our Future: Lessons from Winnie-the-Pooh,” Hastings Center Report 42, no. 4 (2012): 3.

Diekema D. S. , “Parental Refusals of Medical Treatment: The Harm Principle as Threshold for State Intervention,” Theoretical Medicine and Bioethics 25, no. 4 (2004): 243–264.

Id.; 45 C.F.R. § 46.404.

Fernandez C. V. Bouffet E. Malkin D. , “Attitudes of Parents toward the Return of Targeted and Incidental Genomic Research Findings in Children,” Genetics in Medicine 16, no. 8 (2014): 633–636.

Biesecker L. G. Green R. C. , “Diagnostic Clinical Genome and Exome Sequencing,” New England Journal of Medicine 370, no. 25 (2014): 2418–2425.

Blumenthal-Barby J. S. McGuire A. L. Green R. C. Ubel P. A. , “How Behavioral Economics Can Help to Avoid ‘The Last Mile Problem’ in Whole Genome Sequencing,” Genome Medicine 7, no. 1 (2015): 3–5.

Grosse S. D. Boyle C. A. Kenneson A. Khoury M. J. Wilfond B. S. , “From Public Health Emergency to Public Health Service: The Implications of Evolving Criteria for Newborn Screening Panels,” Pediatrics 117, no. 3 (2006): 923–929; Bailey D. B. Jr. Armstrong F. D. Kemper A. R. Skinner D. Warren S. F. , “Supporting Family Adaptation to Presymptomatic and ‘Untreatable’ Conditions in an Era of Expanded Newborn Screening,” Journal of Pediatric Psychology 34, no. 6 (2009): 648–661.